For instance, rationally designed anti-BRAF, anti-EGFR, or anti-p53 mAb have been generated that recognize specifically hotspot mutations in these cancer-relevant proteins, which could be highly valuable for IHC-based precision diagnosis and for novel potential precision therapies.74–76 In addition, the usage of mAb for high-sensitivity biomarker quantification by other methods is also dependent on their specific epitope recognition. This evidence concerns the gene BRAF and cancer.